Drugs
Health-care stocks are projected to exceed market performance in the future due to their superior growth prospects, according to analysts at Sutro & Co. The analysts attribute this growth to the aging population, innovative medical technologies, and emerging markets in the Pacific Rim and Eastern Europe. Sutro & Co., founded
Drugs
R. P. Scherer Corporation, a leading manufacturer of drug delivery systems, has cleared a major hurdle in its planned merger with Cardinal Health, Inc. After receiving shareholder approval, the two companies are now awaiting regulatory clearance to complete the transaction. The merger, which was announced last May, will see stockholders
Drugs
DynaGen, a health care company based in Massachusetts, has announced a restructuring with Superior Pharmaceutical Shareholders, reducing the acquisition purchase price by $5.0 million. This agreement eliminates the $5.0 million common stock payment that was due in June 1998. DynaGen is currently negotiating with several financial institutions to
Drugs
Pentose Pharmaceuticals, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, has received a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) to support the use of its INACTINE technology in eliminating viruses in blood samples collected in evacuated tubes for routine
Drugs
Celgene Corporation recently announced statistically significant weight gain in patients with AIDS-associated weight loss after administration of THALOMID(TM)(thalidomide) for up to six months. The study, presented at the 12th Annual World AIDS Conference in Geneva, showed that patients who received the treatment experienced a mean weight gain of
Drugs
Eli Lilly and Company has announced its financial results for the second quarter of 1998, showing significant growth across various product lines and regions. The company's worldwide sales increased by 18 percent to $2.341 billion, with operating income rising by 14 percent to $641.8 million. Net
Drugs
Eli Lilly and Company, a global research-based pharmaceutical corporation, has purchased Pharsight's modeling and analysis software to aid in their research and development. The software, WinNonlin-Pro, is being deployed in targeted disease areas such as central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular
Drugs
Shire Pharmaceuticals' newly developed Alzheimer's disease drug, made from daffodil bulbs in collaboration with Johnson & Johnson, is generating positive buzz among investors. The company's shares hit an all-time high on Friday, with analysts anticipating favorable results from the Amsterdam conference scheduled for this week.
Drugs
Selective Genetics, Inc. has acquired the exclusive license to U.S. Patent Number 5,763,416, "Gene transfer into bone cells and tissues," which was issued to the University of Michigan on June 9, 1998. The patent covers the company's Gene Activated Matrix (GAM) technology for
Drugs
Schering-Plough, a research-based pharmaceutical company, and Immune Response, a biopharmaceutical company, have entered a research collaboration and option agreement to develop gene therapy products for the treatment of hepatitis B and C, and other diseases. The collaboration combines Immune Response's proprietary GeneDrug gene delivery technology with Schering-Plough'
Drugs
Researchers presented preliminary data at the 12th World AIDS Conference in Geneva that suggests a combination of two investigational drugs, Ziagen (abacavir) and Agenerase (amprenavir), may be effective in treating HIV. The study included 41 patients, with six out of nine patients who completed 48 weeks of treatment showing less
Drugs
Scientists at the World AIDS Conference in Geneva have unveiled the results of a two-year study that shows dramatic improvements in muscle wasting in AIDS patients who took a nonprescription amino acid formula called Juven. The research, led by Dr. Robert Clark, M.D., Director of Ambulatory HIV Services at
